Mark A. Hilfiker - Concepedia

Author

Mark A. Hilfiker

GlaxoSmithKline (United States)

Also Known As

M. A. HILFIKER, Mark A. Hilfiker, Mark Hilfiker

Publications

523

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)University of Pittsburgh South College Pathways Behavioral Services Research Triangle Park Foundation

About

Mark A. Hilfiker is an author at GlaxoSmithKline (United States) specializing in drug discovery, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	150
2	Engineering	3	3	150
3	Natural Sciences	3	3	104
4	Biochemistry	3	3	107
5	Biomolecular Engineering	2	2	69

Mark A. Hilfiker

Publications

494

Citations

H-Index

Page 1

	Year	Citations
A de Novo Enantioselective Total Synthesis of (−)-Laulimalide Scott G. Nelson, Wing S. Cheung, Andrew J. Kassick, Journal of the American Chemical Society	2002	96
Ligand-Modified Catalysts for the McMurry Pinacol Reaction Timothy A. Lipski, Mark A. Hilfiker, Scott G. Nelson The Journal of Organic Chemistry Chemical EngineeringLigand-modified CatalystsEngineeringCross-coupling ReactionChemical Reactions	1997	81
Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell, Journal of Medicinal Chemistry Drug TargetBioorganic ChemistryPharmacotherapyChemical BiologyPharmaceutical Chemistry	2006	71
Asymmetric Synthesis of Monodentate Phosphine Ligands Based on Chiral η<sup>6</sup>-Cr[arene] Templates Scott G. Nelson, Mark A. Hilfiker Organic Letters Asymmetric CatalysisInorganic ChemistryCross-coupling ReactionEngineeringMonodentate Phosphine Ligands	1999	52
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Carl Brooks, Linda S. Barton, David J. Behm, ACS Medicinal Chemistry Letters	2019	51
Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary Edema Mark A. Hilfiker, Tram H. Hoang, Johan Cornil, ACS Medicinal Chemistry Letters Acute Lung InjuryImmunologyPharmacotherapyTrpv4 AntagonistsPharmaceutical Chemistry	2013	30
Enantioenriched Dihydropyrones from β-Lactone Templates Gabriela Zipp, Mark A. Hilfiker, Scott G. Nelson Organic Letters	2002	26
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1 Lara S. Kallander, David G. Washburn, Mark A. Hilfiker, ACS Medicinal Chemistry Letters	2018	21
Discovery of novel aminothiadiazole amides as selective EP3 receptor antagonists Mark A. Hilfiker, Ning Wang, Xiaoping Hou, Bioorganic & Medicinal Chemistry Letters Drug TargetBiochemistryMedicineMechanism Of ActionPharmacological Agent	2009	20
Matrix Isolation Infrared and ab Initio Study of the 1:1 Complexes of Cyclopentadiene with Nitrogen and Oxygen Bases: C−H···N(O) Hydrogen Bonding Involving an sp<sup>3</sup>-Hybridized Carbon Mark A. Hilfiker, Erin R. Mysak, Cindy Samet, The Journal of Physical Chemistry A Chemical EngineeringEngineeringNatural SciencesChemical BondArgon Matrices	2001	17

Page 1